Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer

Active:	No
Cancer Type:	Skin Cancer (Non-Melanoma) Unknown Primary	NCT ID:	NCT04050436
Trial Phases:	Phase II	Protocol IDs:	RPL-002-18 (primary) NCI-2019-06779
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Replimune Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT04050436

Summary

To estimate the clinical benefit of cemiplimab monotherapy versus cemiplimab in
combination with RP1 for patients with locally advanced or metastatic CSCC, as assessed
by overall response rate (ORR) and complete response rate (CRR) according to blinded
independent review.

Objectives

RP1 is a selectively replication competent herpes simplex virus type 1(HSV-1). This is a
Phase 1/2, open-label, multicenter repeat-dosing study of RP1 alone and in combination
with nivolumab in patients with advanced malignancies, and contains both single agent
dose escalation, dose expansion to include nivolumab, and the combination in multiple
Phase 2 cohorts in individual tumor types.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.